您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
会议赞助商
7
2026 - 01 - 27
点击次数:
迪普深合以前沿的诺贝尔奖“点击化学(Click Chemistry)”技术为核心,是全球目前唯一的该技术的商业化实体。公司通过自主开发的“模块化的点击化合物库”构建方法,突破传统化学合成的局限,实现精准、快速的超高通量合成,切实实现以用户为中心,构建专属分子库;并可直接用于活性筛选。公司正全力构建全球领先的点击化学分子砌块库,随着这一点击化合物库的逐步建设与一个个运用点击化学技术的实例落地,公司正逐步成长为药物研发、化妆品、石化、农药及材料科学等领域的探索者与赋能者,为这些行业的合作伙伴提供从源头分子的创新与结构优化,到关键技术的全方位支持;最终有望提高社会整体的科研、化工生产的效率。Core Technology and InnovationDeepSyn Pharmaceutical R&D(Shanghai)Co.,Ltd.(DeepSyn) centers its operations on the cutting-edge, Nobel Prize-winning "Click Chemistry" technology and is currently the world’s only commercial entity dedicated to this technology. Through its proprietary "modular click compound library" construction methodology, the company breaks through the constraints of traditional chemical synthesis. It achieves precise, rapid, and ultra-high-throughput synthesis, focusing on a user-centric approach to build exclusive molecular libraries that can be directly applied to activity screening.Industry Empowerment and VisionThe company is fully committed to establishing a world-leading library of click chemistry molecular building blocks. As this library is progressively developed and practical applications of click chemistry technology are realized, DeepSyn is evolving into an explorer and enabler in several key sectors:· Target Industries: These include pharmaceutical R&D, cosmetics, petrochemicals, pesticides, and materials science7.· Comprehensive Support: The company provides partners with full-spectrum assistance, from the innovation and structural optimization of source molecules to essential technical support.· Social Impact: These efforts are ultimately expected to enhance the overall efficiency of scientific research and industrial chemical production for society.
8
2026 - 01 - 27
点击次数:
成都先导药物开发股份有限公司(上海证券交易所股票代码:688222.SH,股票名称:成都先导)致力于打造国际领先的创新型生物医药企业,总部位于中国成都,在英国剑桥、美国休斯顿设有子公司。公司聚焦小分子及核酸新药的发现与优化,着力打造了国际领先的DNA编码化合物库技术(DEL)平台,并拓展了基于分子片段和三维结构信息的药物设计技术(FBDD/SBDD)、基于寡核苷酸的药物研发技术(OBT)和靶向蛋白降解技术(TPD)的核心技术平台;同时,公司正在建设DEL+AI+自动化DMTA(设计-合成-测试-分析)分子优化能力平台,以期加速临床前候选药物发现及优化过程。通过新药研发服务、不同阶段在研项目转让以及远期的药物上市等多元化的商业模式,成都先导与全球数百家制药公司、生物技术公司、化学公司、基金会以及科研机构建立了合作。目前,公司有多个内部新药项目处于临床及临床前不同阶段。About HitGen Inc.HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.官网链接:https://www.hitgen.com/cn
9
2026 - 01 - 27
点击次数:
蛋白质是生物功能的主要载体,如果能像基因测序一样直接破译蛋白的一级结构,对了解生命活动的分子机制具有重大意义。Rapid Novor一直致力于无需基因序列的蛋白从头测序技术,是全球首个提供单克隆抗体自动化测序服务的公司。目前Rapd Novor拥有全球最大的蛋白测序质谱平台,是蛋白从头测序技术的领跑者。RapdNovor的蛋白从头测序技术已被应用于多发性骨髓瘤MRD监测,可以直接对人血清高浓度单克隆免疫球蛋白进行测序,并获得美国CLIA临床认证。上海快序生物科技有限公司是加拿大Rapid Novor 的中国公司。快序生物在中国提供的服务包括:抗体测序,抗体发现,肿瘤新抗原鉴定服务等。Rapid Novor Shanghai Kuaixu Biotechnologies Co., Ltd. )has the world's leading de novo protein sequencing technologyand is commited to the applicationof this technolosy in the medical field. De novo sequencing is a technique that does not rely on existing DNA or protein database information and directlydetermines the amino acid sequence of proteins. Based on this technology. Rapid Novor(Kuaikxu) has established a new platform for antibody discovery andneoantigen identification. The antibody discovery platform can directly sequence antibody proteins in the serum ofimmunized animals or humans to obtainnatural antibody sequences, thereby significantly shortening the cycle of antibody drug development. However, drect sequencing of the MHC-bound peptidesegmentto obtain the actualpresented neoantigen sequence completely changes the previous discovery mode of neoantigens, which was mainly predicted bythe gene sequencing and algorthm. Rapid Novor (Kuaixu) has always been commited to developing the next generation of protein sequencing technology todecode the immune system and benefit human health.官网链接:https://www.kuaixu.com/
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务